🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against superbug strains of the bacteria, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are escalating worldwide, with data suggesting over 82 million infections per year. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Data and Global Access

Based on findings published in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which involves two antibiotics. The research included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Clinicians treating patients have voiced positive views. Having a single-dose, oral treatment like this is hailed as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.